Teladoc (TDOC) Misses Q2 EPS by 3c, Revenues Beat; Guides Revs Above

Go back to Teladoc (TDOC) Misses Q2 EPS by 3c, Revenues Beat; Guides Revs Above

Teladoc (TDOC) PT Raised to $86 at Chardan Capital Markets

August 3, 2018 6:39 AM EDT

Chardan Capital Markets raised its price target on Teladoc (NYSE: TDOC) to $86.00 (from $73.00) while maintaining a Buy rating.

Analyst Steven Wardell commented, "After market close on Wed., TDOC reported revenue and earnings that beat "consensus, and raised its 2018 guide. TDOCs... More

Teladoc (TDOC) PT Raised to $68 at Oppenheimer

August 2, 2018 9:32 AM EDT

Oppenheimer raised its price target on Teladoc (NYSE: TDOC) to $68.00 (from $59.00) while maintaining a Outperform rating.

Analyst Mohan Naidu commented, "Teladoc Health (as the company has renamed itself) beat our and consensus expectations for revenues and EBITDA at $95M/$2.7M... More

Teladoc (TDOC) PT Raised to $52 at Cantor Fitzgerald Following 2Q

August 2, 2018 8:21 AM EDT

Cantor Fitzgerald raised its price target on Teladoc (NYSE: TDOC) to $52.00 (from $50.00) while maintaining a Neutral rating following the company's 2Q release. Revenue was $94.6 million vs. consensus of $92M. U.S. paid visits grew 41%.

Given the strong growth and including Advance Medical, TDOC... More

Teladoc (TDOC) PT Raised to $77 at Piper Jaffray Following 2Q Report

August 2, 2018 7:13 AM EDT

Piper Jaffray raised its price target on Teladoc (NYSE: TDOC) to $77.00 (from $55.00) while maintaining an Overweight rating following the company's 2Q earnings report. Total revenue of $94.6M was up 112% on an absolute basis and 39% organically, and beat Consensus estimates of $91.9M. EBITDA of... More